Meeting
2018 ASCO Annual Meeting
Randomized, double-blind, phase III trial of monosialotetrahexosylganglioside versus placebo in GI cancer patients with oxaliplatin induced peripheral neurotoxicity (TJMUCH-GI-001).
Authors
Zhou Likun
Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy Tianjin Medical University, Tianjin, China
Zhou Likun , Yi Ba , Rui Liu , Dingzhi Huang , Hongli Li , Tao Ning Sr., Le Zhang , Shaohua Ge , Ming Bai , Xia Wang , Rubing Han , Yuchong Yang , XinYi Wang , Zhiying Gao , Xinyun Chen , Kaijun Niu , Laizhi Luo , Ting Deng , Yan Li , Yuanquan Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT02486198
Citation
J Clin Oncol 36, 2018 (suppl; abstr 10017)
DOI
10.1200/JCO.2018.36.15_suppl.10017
Abstract #
10017
Poster Bd #
5
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Survival and safety of monosialotetrahexosylganglioside in GI cancer patients with oxaliplatin-induced peripheral neurotoxicity-result from TJMUCH-GI-001 trial.
First Author: Zhou Likun
Poster
2019 Gastrointestinal Cancers Symposium
Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside in prevention of oxaliplatin-induced neurotoxicity in stage II/III colorectal cancer patients.
First Author: Yu-hong Li
Poster
2016 ASCO Annual Meeting
A multicenter, randomized, double-blind, placebo-controlled phase III study of monosialoganglioside (GM1) preventing neurotoxicity induced by cisplatin-based chemotherapy in non-small cell lung cancer patients.
First Author: Li Zhang
Poster
2023 ASCO Annual Meeting
Pharmacological cardioprotective strategy for non-metastatic patients affected by breast cancer receiving an anthracycline-based chemotherapy: Final results of the phase 3 SAFE trial.
First Author: Lorenzo Livi